無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ワクチンの世界市場:技術 (生、トキソイド、遺伝子組み換え)・疾患 (肺炎球菌、インフルエンザ、DTP、HPV、肝炎、髄膜炎菌性疾患、ロタウイルス、小児まひ、MMR、水痘、デング熱)・投与経路 (筋肉内/皮下投与、経口投与)・患者 (小児、成人)・種類別の予測 (2023年まで)

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023

発行 MarketsandMarkets 商品コード 278597
出版日 ページ情報 英文 185 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
ワクチンの世界市場:技術 (生、トキソイド、遺伝子組み換え)・疾患 (肺炎球菌、インフルエンザ、DTP、HPV、肝炎、髄膜炎菌性疾患、ロタウイルス、小児まひ、MMR、水痘、デング熱)・投与経路 (筋肉内/皮下投与、経口投与)・患者 (小児、成人)・種類別の予測 (2023年まで) Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023
出版日: 2018年08月14日 ページ情報: 英文 185 Pages
概要

世界のワクチン市場は、2018年には364億5000万米ドル、2023年には504億2000万米ドルと、6.7%のCAGR (複合年間成長率) で拡大する見通しです。市場の主要な成長要因として、各種疾患の患者数の多さや、政府や民間団体からのワクチン開発への援助、企業の研究開発 (R&D) 強化などが挙げられます。

当レポートでは、世界のワクチン市場について分析し、製品の概要や、市場の基本構造・最新情勢、主な市場促進・阻害要因、市場動向と今後の見通し (過去2年間・今後6年間分)、技術別・種類別・疾患別・投薬経路別・患者別・地域別の詳細動向、市場競争の状態、今後の技術開発・市場発展の方向性、主要企業のプロファイルなどを調査しております。

FIGURE 12 THE VACCINES MARKET

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場のダイナミクス
    • 促進要因
      • 感染症の有病者率の高さ
      • 予防接種事業への関心増大
      • ワクチン開発への政府助成金の増額
      • ワクチンの研究開発 (R&D) に対する企業の取り組み強化
    • 抑制要因
      • ワクチン開発費用の高さ
    • 市場機会
      • 新興国市場での急成長の見通し
      • 治療用ワクチンへの関心
      • ワクチンとしてのアジュバント (助剤) の利用
    • 課題
      • ワクチン入手の難しさ
      • 製品リコール

第6章 産業分析

  • 世界各国の規制環境
  • 主なパイプライン製品
  • 新型ワクチンの市場機会
    • HIVワクチン
      • 製品パイプライン
      • 官民連携事業 (PPI)
      • 資金調達
    • マラリアワクチン
    • ジカワクチン
    • エボラワクチン

第7章 ワクチン市場:技術別

  • イントロダクション
  • 結合型ワクチン
  • 不活性化・サブユニットワクチン
  • 弱毒化生ワクチン
  • 遺伝子組み換えワクチン
  • トキソイドワクチン

第8章 ワクチン市場:種類別

  • イントロダクション
  • 単価ワクチン
  • 多価ワクチン

第9章 ワクチン市場:適応症別

  • イントロダクション
  • 肺炎球菌性疾患
  • DTP (三種混合ワクチン)
  • インフルエンザ
  • ヒトパピローマウイルス (HPV)
  • 髄膜炎菌性疾患
  • ポリオ (小児まひ)
  • ロタウィルス
  • 肝炎
  • MMR (新三種混合ワクチン)
  • 水痘
  • デング熱
  • 帯状疱疹
  • その他

第10章 ワクチン市場:投与経路別

  • イントロダクション
  • 筋肉内・皮下投与 (IM, SC)
  • 経口投与
  • その他

第11章 ワクチン市場:患者の種類別

  • イントロダクション
  • 小児
  • 成人

第12章 ワクチン市場:地域別

  • イントロダクション
  • 北米 (米国、カナダ)
  • 欧州 (ドイツ、英国、フランス、イタリア、スペインなど)
  • アジア (日本、中国、インドなど)
  • 他の国々 (RoW)

第13章 競争環境

  • イントロダクション
  • 市場シェア分析
  • 競争状況と動向
    • 事業提携・協力、合意
    • 製品発売・認証
    • 企業買収
    • 事業拡張

第14章 企業プロファイル (事業概要、主要製品、近年の動向、SWOT分析、MnMの見解)

  • PFIZER
  • GLAXOSMITHKLINE
  • MERCK
  • SANOFI PASTEUR
  • CSL LIMITED
  • EMERGENT BIOSOLUTIONS
  • JOHNSON & JOHNSON
  • MEDIMMUNE, LLC (ASTRAZENECAの子会社)
  • アステラス製薬
  • SERUM INSTITUTE OF INDIA
  • BAVARIAN NORDIC
  • 田辺三菱製薬
  • 第一三共
  • PANACEA BIOTEC
  • BIOLOGICAL E

第15章 付録

図表

LIST OF TABLES

  • TABLE 1: INCIDENCE OF DISEASES
  • TABLE 2: NIH FUNDING FOR VACCINE RESEARCH, 2013-2018 (USD MILLION)
  • TABLE 3: IMMUNIZATION COVERAGE, BY DISEASE, 2015 VS 2016
  • TABLE 4: REGULATORY AUTHORITIES IN EUROPE
  • TABLE 5: REGULATORY AUTHORITIES IN ASIA
  • TABLE 6: KEY PIPELINE VACCINES
  • TABLE 7: ESTIMATED INVESTMENTS IN HIV VACCINES, BY INVESTOR (2015-2016)
  • TABLE 8: EBOLA PROJECTS FUNDED BY EC (2014-2020)
  • TABLE 9: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 10: COST OF MENINGOCOCCAL CONJUGATE VACCINES
  • TABLE 11: CONJUGATE VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 12: EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES
  • TABLE 13: INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 14: LIVE ATTENUATED VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 15: EXAMPLES OF RECOMBINANT VACCINES
  • TABLE 16: RECOMBINANT VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 17: TOXOID VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 18: VACCINES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 19: MONOVALENT VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 20: EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET
  • TABLE 21: MULTIVALENT VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 22: VACCINES MARKET, BY DISEASE INDICATION, 2016-2023 (USD MILLION)
  • TABLE 23: LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET
  • TABLE 24: VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 25: LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
  • TABLE 26: VACCINES MARKET FOR DTP, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 27: LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
  • TABLE 28: VACCINES MARKET FOR INFLUENZA, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 29: LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
  • TABLE 30: VACCINES MARKET FOR HPV, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 31: LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
  • TABLE 32: VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 33: LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET
  • TABLE 34: VACCINES MARKET FOR POLIO, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 35: LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
  • TABLE 36: VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 37: LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
  • TABLE 38: VACCINES MARKET FOR HEPATITIS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 39: LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
  • TABLE 40: VACCINES MARKET FOR MMR, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 41: LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
  • TABLE 42: VACCINES MARKET FOR VARICELLA, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 43: VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 44: LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS IN THE MARKET
  • TABLE 45: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 46: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD MILLION)
  • TABLE 47: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 48: VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 49: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 50: VACCINES MARKET, BY PATIENT TYPE, 2016-2023 (USD MILLION)
  • TABLE 51: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 52: NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 53: VACCINES MARKET FOR ADULT PATIENTS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 54: NORTH AMERICA: VACCINES MARKET FOR ADULT PATIENTS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 55: VACCINES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 56: NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 57: NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 58: NORTH AMERICA: VACCINES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 59: NORTH AMERICA: VACCINES MARKET, 2016-2023 (USD MILLION)
  • TABLE 60: NORTH AMERICA: VACCINES MARKET, 2016-2023 (USD MILLION)
  • TABLE 61: NORTH AMERICA: VACCINES MARKET, BY PATIENT TYPE, 2016-2023 (USD MILLION)
  • TABLE 62: US: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 63: US: VACCINES MARKET, BY PATIENT TYPE, 2016-2023 (USD MILLION)
  • TABLE 64: CANADA: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 65: CANADA: VACCINES MARKET, BY PATIENT TYPE, 2016-2023 (USD MILLION)
  • TABLE 66: EUROPE: VACCINES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 67: EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 68: EUROPE: VACCINES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 69: EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2016-2023 (USD MILLION)
  • TABLE 70: EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD MILLION)
  • TABLE 71: EUROPE: VACCINES MARKET, BY PATIENT TYPE, 2016-2023 (USD MILLION)
  • TABLE 72: GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 73: UK: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 74: FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 75: ITALY: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 76: SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 77: ROE: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 78: ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000, 2014 & 2016 (USD)
  • TABLE 79: ASIA: VACCINES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 80: ASIA: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 81: ASIA: VACCINES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 82: ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2016-2023 (USD MILLION)
  • TABLE 83: ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 (USD MILLION)
  • TABLE 84: ASIA: VACCINES MARKET, BY PATIENT TYPE, 2016-2023 (USD MILLION)
  • TABLE 85: JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 86: CHINA: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 87: INDIA: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 88: ROA: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 89: ROW: VACCINES MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 90: ROW: VACCINES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 91: ROW: VACCINES MARKET, 2016-2023 (USD MILLION)
  • TABLE 92: ROW: VACCINES MARKET, 2016-2023 (USD MILLION)
  • TABLE 93: ROW: VACCINES MARKET, BY PATIENT TYPE, 2016-2023 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: VACCINES MARKET SEGMENTATION
  • FIGURE 2: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: VACCINES MARKET, BY TECHNOLOGY, 2018-2023
  • FIGURE 7: VACCINES MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 8: VACCINES MARKET, BY DISEASE INDICATION, 2018 VS. 2023 (USD BILLION)
  • FIGURE 9: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 VS. 2023 (USD BILLION)
  • FIGURE 10: VACCINES MARKET, BY PATIENT TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 11: GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET
  • FIGURE 12: HIGH PREVALENCE OF DISEASES AND RISING FOCUS ON IMMUNIZATION PROGRAMS ARE DRIVING MARKET GROWTH
  • FIGURE 13: MONOVALENT VACCINES SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 14: PEDIATRICS SEGMENT TO DOMINATE THE VACCINES MARKET IN 2023 (USD BILLION)
  • FIGURE 15: CONJUGATE VACCINES SEGMENT TO HOLD LARGEST SHARE OF THE VACCINES MARKET IN 2018
  • FIGURE 16: INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 17: US TO DOMINATE THE VACCINES MARKET IN 2018
  • FIGURE 18: VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19: REGULATORY APPROVAL PROCESS FOR VACCINES
  • FIGURE 20: R&D FUNDING FOR HIV PREVENTIVE VACCINES, BY INVESTOR, 2016
  • FIGURE 21: CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINES MARKET DURING THE FORECAST PERIOD
  • FIGURE 22: MONOVALENT VACCINES TO GROW AT THE HIGHEST RATE IN THE VACCINES MARKET, BY TYPE
  • FIGURE 23: PNEUMOCOCCAL DISEASE SEGMENT TO LEAD VACCINES MARKET, BY DISEASE INDICATION, DURING 2018-2023
  • FIGURE 24: VACCINES MARKET FOR DENGUE, 2016-2023 (USD MILLION)
  • FIGURE 25: INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO ACCOUNT FOR THE VACCINES MARKET, 2018-2023 (USD MILLION)
  • FIGURE 26: PEDIATRIC PATIENTS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE VACCINES MARKET, 2018 (USD MILLION)
  • FIGURE 27: NORTH AMERICA: VACCINES MARKET SNAPSHOT
  • FIGURE 28: EUROPE: VACCINES MARKET SNAPSHOT
  • FIGURE 29: ASIA: VACCINES MARKET SNAPSHOT
  • FIGURE 30: ROW: VACCINES MARKET SNAPSHOT
  • FIGURE 31: KEY DEVELOPMENTS IN THE VACCINE MARKET FROM 2015 TO 2018
  • FIGURE 32: MARKET EVOLUTION FRAMEWORK
  • FIGURE 33: VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017
  • FIGURE 34: PFIZER: COMPANY SNAPSHOT (2017)
  • FIGURE 35: GLAXOSMITHKLINE: COMPANY SNAPSHOT (2017)
  • FIGURE 36: MERCK: COMPANY SNAPSHOT (2017)
  • FIGURE 37: SANOFI PASTEUR: COMPANY SNAPSHOT (2017)
  • FIGURE 38: CSL LIMITED: COMPANY SNAPSHOT (2017)
  • FIGURE 39: EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT (2017)
  • FIGURE 40: JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017)
  • FIGURE 41: ASTRAZENECA: COMPANY SNAPSHOT (2017)
  • FIGURE 42: ASTELLAS PHARMA: COMPANY SNAPSHOT (2017)
  • FIGURE 43: BAVARIAN NORDIC: COMPANY SNAPSHOT (2017)
  • FIGURE 44: MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT (2017)
  • FIGURE 45: DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2017)
  • FIGURE 46: PANACEA BIOTEC: COMPANY SNAPSHOT (2017)
目次
Product Code: PH 6528

"Global vaccines market projected to grow at a CAGR of 6.7%"

The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development.

"Monovalent vaccines segment expected to hold the largest share of the market in 2018."

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.

"Pneumococcal disease segment is expected to hold largest share of the market in 2018"

Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share of the vaccines market in 2018. The large share of this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal diseases.

"Asia to witness high growth during the forecast period"

In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 36%; Tier 2 - 41%; Tier 3 - 23%.
  • By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
  • By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
  • By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report:

  • GlaxoSmithKline plc (US)
  • Pfizer, Inc. (US)
  • Merck & Co., Inc. (US)
  • Sanofi Pasteur SA (France)
  • CSL Limited (Australia)
  • Emergent BioSolutions, Inc. (US)
  • Johnson & Johnson (US)
  • MedImmune, LLC (US)
  • Astellas Pharma Inc. (Japan)
  • Serum Institute of India (India)
  • Bavarian Nordic (Denmark)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Daiichi Sankyo Company, Limited (Japan)
  • Biological E (India)
  • Panacea Biotec (India)

Research Coverage:

The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKET COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DESIGN
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. OVERVIEW OF THE VACCINES MARKET
  • 4.2. VACCINES MARKET, BY TYPE, 2018-2023
  • 4.3. VACCINES MARKET, BY END USER, 2018 VS. 2023(USD BILLION)
  • 4.4. GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY
  • 4.5. VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 VS. 2023(USD BILLION)
  • 4.6. GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. High prevalence of infectious diseases
      • 5.2.1.2. Rising focus on immunization programs
      • 5.2.1.3. Growing government support for vaccine development
      • 5.2.1.4. Increasing company initiatives to enhance vaccine R&D
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. High cost of vaccine development
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. High growth prospects in emerging markets
      • 5.2.3.2. Focus on therapeutic vaccines
      • 5.2.3.3. Use of adjuvants in vaccines
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Inadequate access to vaccines
      • 5.2.4.2. Product recalls

6. INDUSTRY INSIGHTS

  • 6.1. REGULATORY LANDSCAPE
    • 6.1.1. NORTH AMERICA
    • 6.1.2. EUROPE
    • 6.1.3. ASIA
    • 6.1.4. ROW
  • 6.2. KEY PIPELINE PRODUCTS
  • 6.3. NEW VACCINE OPPORTUNITIES
    • 6.3.1. HIV
      • 6.3.1.1. HIV vaccine: product pipeline
      • 6.3.1.2. HIV vaccine: public-private initiatives
      • 6.3.1.3. HIV vaccine: funding
    • 6.3.2. MALARIA
      • 6.3.2.1. Malaria vaccine: product pipeline
      • 6.3.2.2. Malaria vaccine: public-private initiatives
    • 6.3.3. ZIKA
      • 6.3.3.1. Zika vaccine: product pipeline
      • 6.3.3.2. Zika vaccine: public-private initiatives
      • 6.3.3.3. Zika vaccine: funding
    • 6.3.4. EBOLA
      • 6.3.4.1. Ebola vaccine: product pipeline
      • 6.3.4.2. Ebola vaccine: public-private initiatives
      • 6.3.4.3. Ebola vaccine: funding

7. VACCINES MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. CONJUGATE VACCINES
  • 7.3. INACTIVATED AND SUBUNIT VACCINES
  • 7.4. LIVE ATTENUATED VACCINES
  • 7.5. RECOMBINANT VACCINES
  • 7.6. TOXOID VACCINES

8. VACCINES MARKET, BY TYPE

  • 8.1. INTRODUCTION
  • 8.2. MONOVALENT VACCINES
  • 8.3. MULTIVALENT VACCINES

9. VACCINES MARKET, BY DISEASE INDICATION

  • 9.1. INTRODUCTION
  • 9.2. PNEUMOCOCCAL DISEASE
  • 9.3. DTP
  • 9.4. INFLUENZA
  • 9.5. HPV
  • 9.6. MENINGOCOCCAL DISEASE
  • 9.7. POLIO
  • 9.8. ROTAVIRUS
  • 9.9. HEPATITIS
  • 9.10. MMR
  • 9.11. VARICELLA
  • 9.12. DENGUE
  • 9.13. HERPES ZOSTER
  • 9.14. OTHER DISEASE INDICATIONS

10. VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 10.1. INTRODUCTION
  • 10.2. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
  • 10.3. ORAL ADMINISTRATION
  • 10.4. OTHER ROUTES OF ADMINISTRATION

11. VACCINES MARKET, BY PATIENT TYPE

  • 11.1. INTRODUCTION
  • 11.2. PEDIATRIC PATIENTS
  • 11.3. ADULT PATIENTS

12. VACCINES MARKET, BY REGION

  • 12.1. INTRODUCTION
  • 12.2. NORTH AMERICA
    • 12.2.1. US
    • 12.2.2. CANADA
  • 12.3. EUROPE
    • 12.3.1. GERMANY
    • 12.3.2. UK
    • 12.3.3. FRANCE
    • 12.3.4. ITALY
    • 12.3.5. SPAIN
    • 12.3.6. ROE
  • 12.4. ASIA
    • 12.4.1. JAPAN
    • 12.4.2. CHINA
    • 12.4.3. INDIA
    • 12.4.4. REST OF ASIA (ROA)
  • 12.5. REST OF THE WORLD (ROW)

13. COMPETITIVE LANDSCAPE

  • 13.1. OVERVIEW
  • 13.2. MARKET SHARE ANALYSIS
  • 13.3. COMPETITIVE SITUATION AND TRENDS
    • 13.3.1. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 13.3.2. PRODUCT LAUNCHES AND APPROVALS
    • 13.3.3. ACQUISITIONS
    • 13.3.4. EXPANSIONS

14. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, MnM View)*

  • 14.1. PFIZER
  • 14.2. GLAXOSMITHKLINE
  • 14.3. MERCK
  • 14.4. SANOFI PASTEUR
  • 14.5. CSL LIMITED
  • 14.6. EMERGENT BIOSOLUTIONS
  • 14.7. JOHNSON & JOHNSON
  • 14.8. MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA)
  • 14.9. ASTELLAS PHARMA
  • 14.10. SERUM INSTITUTE OF INDIA
  • 14.11. BAVARIAN NORDIC
  • 14.12. MITSUBISHI TANABE PHARMA CORPORATION
  • 14.13. DAIICHI SANKYO COMPANY
  • 14.14. PANACEA BIOTEC
  • 14.15. BIOLOGICAL E

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

15. APPENDIX

  • 15.1. DISCUSSION GUIDE
  • 15.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3. AVAILABLE CUSTOMIZATIONS
  • 15.4. RELATED REPORTS
  • 15.5. AUTHOR DETAILS
Back to Top